LOTTE BIOLOGICS has announced the appointment of James Park as its new CEO, effective after an upcoming extraordinary general meeting of shareholders and a board meeting. Park, 58, brings over two decades of experience in the pharmaceutical and biotechnology industries,
Lotte Biologics has embarked on a significant expansion in the biopharmaceutical sector with the groundbreaking ceremony for its bio campus in Songdo International City, Incheon. The event, attended by key figures including Lotte Group Chairman Shin Dong-bin and CEO Lee
LOTTE BIOLOGICS is a CMO/CDMO company operating in the pharmaceutical industry. LOTTE BIOLOGICS is a premier global CDMO dedicated to providing top-quality biopharmaceuticals. We have pursued swift global expansion following the acquisition of BMS’ Syracuse site, a location with over
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
